Sun Pharma Investor Presentation: Financial Performance and Strategic Highlights
Sun Pharmaceutical Industries Ltd 路 Investor Presentation 路 23 Sept 2026, 1:03 am
Sun Pharma Investor Presentation: Financial Performance and Strategic Highlights Sun Pharma reported Q1 FY27 gross sales of Rs 151,836 mn, up 10.1% YoY, driven by India formulations (+16.0% YoY to Rs 54,749 mn) and Emerging Markets (+15.4% YoY to Rs 29,456 mn). EBITDA reached Rs 44,177 mn with a 28.9% margin, while adjusted net profit grew 3.1% YoY to Rs 30,894 mn. For FY26, sales totaled Rs 582,201 mn (+11.9% YoY) with Innovative Medicines contributing 22% (USD 1,420 mn). As of 7th Sep'26, market capitalization stood at USD 48 Bn (Rs 4,545 Bn).
Original exchange filing (PDF)
More announcements from Sun Pharmaceutical Industries Ltd
- Intimation of Schedule of Analyst/Institutional Investor Meeting 路 05 Nov 2026
- Q2FY27 Earnings Call Transcript 路 05 Nov 2026
- Clarification regarding news report relating to the Company''s Assam facility 路 03 Nov 2026
- The Exchange has sought clarification from Sun Pharmaceutical Industries Ltd on November 2, 2026, with reference to news appeared in https://www.thehindu.com/ dated October 30, 2026 quoting .... 路 02 Nov 2026
- Completion and results of postal ballot dated 01 October 2026 路 01 Nov 2026
- Q2FY27- Investor Call Audio Recording 路 31 Oct 2026
- Board Meeting Outcome - Conclusion 路 30 Oct 2026
- Unaudited Financial Results for the quarter and half year ended 30 September 2026 路 30 Oct 2026
